European registry for newly diagnosed AL amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have AL amyloidosis (light chain amyloidosis).
- You have not had any prior treatment for this condition.
- You are 18 years of age or older.
- You agree to sign a consent form and are willing to be followed at a participating center.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
This study collects blood and tissue samples and health data from people with amyloidosis to build a biobank and registry. Researchers hope this will help improve future diagnosis and treatment.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This study creates a registry for people diagnosed with systemic amyloidosis in Hungary. It helps doctors better understand the condition by collecting medical history and tracking outcomes over time.
This trial tests an experimental treatment using your own immune cells, modified in the lab, to target and destroy the cells that cause AL amyloidosis. It is for people who are newly diagnosed and have severe heart involvement, with the goal of slowing or stopping the disease.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.